Introduction
============

The progressively increasing number of the elderly in the general population and, consequently, the growing prevalence of Alzheimer disease[@b1-cia-6-207],[@b2-cia-6-207] (AD) highlight the need for new specifically targeted therapeutic options.[@b3-cia-6-207]--[@b6-cia-6-207] The currently available psychological[@b7-cia-6-207]--[@b10-cia-6-207] and psychopharmacological[@b11-cia-6-207]--[@b15-cia-6-207] treatments[@b16-cia-6-207] for AD provide relatively poor results. The inadequate and/or insufficient safety and tolerability profile of 'typical' AD therapies produce familiar social and economic difficulties.[@b17-cia-6-207],[@b18-cia-6-207] According to the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision (DSM-IV-TR), AD includes a disruption in attention,[@b19-cia-6-207],[@b20-cia-6-207] concentration, memory,[@b21-cia-6-207],[@b22-cia-6-207] and cognition.[@b23-cia-6-207] While the DSM-IV-TR instructs diagnosing clinicians to specify whether cognitive symptoms of AD are accompanied by behavioral abnormalities (eg, delusions, depression, anxiety, agitation, wandering, sexual behavior alterations, sleep dysfunctions, disorientation), behavioral symptoms of AD are not included in the working definition.

The relationship between AD and the behavioral and psychiatric symptoms of dementia[@b24-cia-6-207] (BPSD) is becoming more prevalent. Symptoms of dementia accompany AD in about 90% of cases,[@b25-cia-6-207] typically arising early in the course of the disease and persisting. Unlike the steady loss of "global" cognition, throughout the course of AD, behavioral symptoms are more variable, with different types of BPSD seen among patients.[@b26-cia-6-207] Despite the observed inter-patient variability in number and type of behavioral symptoms encountered in AD, patients with advanced illness tend to have more behavioral symptoms than those in earlier phases of the disorder. Several long-term studies indicate that once a specific symptom occurs in a given patient, it is likely to persist or recur thereafter.

Radio electric asymmetric brain stimulation[@b27-cia-6-207],[@b28-cia-6-207] (REAC) treatment has proven efficacy in ameliorating several stress-related disorders, depression, and anxiety,[@b29-cia-6-207]--[@b35-cia-6-207] and our unpublished data have shown promising results for some forms of dementias. REAC treatments are painless, noninvasive, and have a high safety and tolerability profile. On the basis these we can hypothesize that the treatments with REAC technology may be helpful in AD and, in general, in several forms of cognitive-impairment disorders.

Aim of the present study
------------------------

REAC has demonstrated efficacy in improving certain psychiatric disorders such as anxiety, depression and bipolar disorder. The main goal of the present study was to investigate the efficacy of REAC in the treatment of behavioral symptoms in AD patients. In addition, effects on cognitive functioning were also investigated.

Materials and methods
=====================

The data for the current study were collected during routine therapy sessions at the Rinaldi Fontani Institute, Behavioral Disorder Department in Florence, Italy. Most patients referred to the clinic were nonresponders to typical pharmacological strategies. Eight patients (five females and three males; mean \[±SD\] age at study baseline: 69.9 ± 3.0 years) diagnosed with AD according to the DSM-IV-TR criteria (mean onset age of AD: 65.4 ± 3.5 years), presenting with behavioral and/or psychiatric disturbances were psychometrically assessed using the Mini-Mental State Examination[@b36-cia-6-207] (MMSE), the Activity of Daily Living[@b37-cia-6-207] (ADL), the Instrumental Activity of Daily Living[@b38-cia-6-207] (IADL), and the Neuropsychiatric Inventory[@b39-cia-6-207] (NPI), before and after 2 treatment cycles of REAC.

REAC is applied by a medical device that is based on an innovative biostimulation technology.[@b27-cia-6-207],[@b28-cia-6-207] REAC works within a typical frequency range of 2.4, 5.8, or 10.5 GHz, selected by the operator for each specific protocol. For the current study, a frequency of 10.5 GHz, with a specific absorption rate (SAR) of 7 μW/kg, was used. The neuro postural optimization (NPO) protocol consisting of a single radiofrequency burst of 500 milliseconds (ms) applied by touching the metallic tip of the REAC probe (Convogliatore di Radianza Modulante -- CRM; ASMED, Italy) to the ear pavilion was performed as an initial treatment. NPO was followed by another treatment protocol, named neuro psycho physical optimization (NPPO). This protocol consisting of seven REAC radiofrequency bursts of 500 ms applied by touching the metallic tip of the REAC probe at precise points of the ear. Each therapy session lasts about 5 seconds. An NPPO treatment cycle consists of 18 therapy sessions, administered on alternate days. The mean interval between the first and the second NPPO treatment cycle is about 6 months.

ANOVA for repeated measures was performed for statistical analysis of differences in MMSE, ADL, IADL, and NPI scores prior to and following REAC treatments. *P* values \<0.05 were considered significant.

Results
=======

After the first REAC treatment cycle, patients showed great improvement in cognitive performance as demonstrated by a significant increase in average MMSE total score from 18.5 (±2.4) to 23.4 (±2.3) (ANOVA *P* \< 0.01) ([Table 1](#t1-cia-6-207){ref-type="table"} and [Figure 1](#f1-cia-6-207){ref-type="fig"}). In addition, BPSD was improved as demonstrated by a decrease in average NPI frequency score ([Table 1](#t1-cia-6-207){ref-type="table"} and [Figure 2](#f2-cia-6-207){ref-type="fig"}) from 32.2 (±2.5) to 26.4 (±2.4) (ANOVA *P* = 0.000), NPI severity score ([Table 1](#t1-cia-6-207){ref-type="table"} and [Figure 2](#f2-cia-6-207){ref-type="fig"}) from 28.6 (±3.4) to 22.1 (±3.4) (ANOVA *P* = 0.000), and NPI distress score from ([Table 1](#t1-cia-6-207){ref-type="table"} and [Figure 2](#f2-cia-6-207){ref-type="fig"}) 49.5 (±3.6) to 41.0 (±2.1) (ANOVA *P* = 0.000). In addition, average ADL score ([Table 1](#t1-cia-6-207){ref-type="table"} and [Figure 3](#f3-cia-6-207){ref-type="fig"}) increased from 3.8 (±1.0) to 4.9 (±0.5) (ANOVA *P* = NS) and average IADL score ([Table 1](#t1-cia-6-207){ref-type="table"} and [Figure 4](#f4-cia-6-207){ref-type="fig"}) increased from 10.0 (±2.4) to 13.0 (±1.1) (ANOVA *P* = 0.000).

After the second REAC treatment cycle, there were further significant ameliorations in both cognitive and behavioral performance ([Table 2](#t2-cia-6-207){ref-type="table"}). There was a significant increase in average MMSE total score ([Table 2](#t2-cia-6-207){ref-type="table"} and [Figure 1](#f1-cia-6-207){ref-type="fig"}) to 26.0 (±3.4) (ANOVA *P* \< 0.001), and a significant decrease in NPI frequency score ([Table 2](#t2-cia-6-207){ref-type="table"} and [Figure 2](#f2-cia-6-207){ref-type="fig"}) to 23.3 (±2.3) (ANOVA *P* \< 0.001), NPI severity score ([Table 2](#t2-cia-6-207){ref-type="table"} and [Figure 2](#f2-cia-6-207){ref-type="fig"}) to 18.2 (± 3.7) (ANOVA *P* = 0.000), and NPI distress score ([Table 2](#t2-cia-6-207){ref-type="table"} and [Figure 2](#f2-cia-6-207){ref-type="fig"}) to 36.7 (±4.3) (ANOVA *P* = 0.000). IADL total score was significantly increased after the second REAC treatment to 14.4 (±0.7) (ANOVA *P* = NS) ([Table 2](#t2-cia-6-207){ref-type="table"} and [Figure 4](#f4-cia-6-207){ref-type="fig"}). The increase in ADL total score to 5.1 ± 0.4 ([Table 2](#t2-cia-6-207){ref-type="table"} and [Figure 3](#f3-cia-6-207){ref-type="fig"}) was not statistically significant (ANOVA *P* = NS).

Discussion
==========

REAC treatment enhanced cognitive and behavioral functioning in patients with AD. All measures of cognitive functioning were significantly improved after the initial REAC treatment and continued to improve after the second REAC cycle. Similarly, all behavioral measurements were positively affected after the first REAC treatment and most continued to improve after the second cycle.

It is likely that the effects on cognition and behavior are due to a process of synchronization of brain function caused by the microelectric stimulation of the REAC.[@b29-cia-6-207]

While cognitive functioning benefitted from REAC treatment, the positive effects on BPSD may be of more importance in the management of AD patients. The improvement in these clinical parameters is reflected in functional terms by an increase in the quality of life of patients as reported by relatives, physicians, and care-givers and is psychometrically demonstrated by the ADL and IADL total scores. The use of REAC treatment may decrease the need to continually alter pharmacological treatments to achieve optimal results, leading to significant savings in economic resources of rehabilitation programs for AD patients.

REAC treatments alone are not likely to manage all deficits associated with neuropsychiatric disorders in the elderly. However, the results of the present study suggest that REAC treatment has a high safety, tolerability, and efficacy profile and may be useful not only in patients who have experienced poor and/or unstable responses to psychotropic drugs, but also as a first-line therapeutic option. REAC treatment may be useful not only for AD patients, but also for other forms of dementia (ie, vascular dementia or mixed conditions).
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###### 

Total score variation before and after first REAC treatment cycle

  **Test**              **TSV before REAC**   **TSV after 1 REAC cycle**   **ANOVA *F***   ***df***   ***P***
  --------------------- --------------------- ---------------------------- --------------- ---------- ---------
  MMSE                  18.5 ± 2.4            23.4 ± 2.3                   64.0588         14         \<0.01
  NPI for "frequency"   32.2 ± 2.5            26.4 ± 2.4                   309.8421        14         0.000
  NPI for "severity"    28.6 ± 3.4            22.1 ± 3.4                   529.000         14         0.000
  NPI for "distress"    49.5 ± 3.6            41.0 ± 2.1                   583.1538        14         0.000
  ADL                   3.8 ± 1.0             4.9 ± 0.5                    33.8507         14         NS
  IADL                  10.0 ± 2.4            13.0 ± 1.1                   134.8667        14         0.000

**Abbreviations:** REAC, radio electric asymmetric brain stimulation; TSV, total score variation; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric inventory; ADL, Activity of Daily Living; IADL, Instrumental Activity of Daily Living; NS, not statistically significant.

###### 

Total score value of first versus second REAC treatment cycle

  **Test**              **TSV after 1 REAC cycle**   **TSV after 2 REAC cycle**   **ANOVA *F***   ***df***   ***P***
  --------------------- ---------------------------- ---------------------------- --------------- ---------- ---------
  MMSE                  23.4 ± 2.3                   26.0 ± 3.4                   44.800          14         \<0.001
  NPI for "frequency"   26.4 ± 2.4                   23.3 ± 2.3                   79.5455         14         \<0.001
  NPI for "severity"    22.1 ± 3.4                   18.2 ± 3.7                   203.8936        14         0.000
  NPI for "distress"    41.0 ± 2.1                   36.7 ± 4.3                   191.6526        14         \<0.05
  ADL                   4.9 ± 0.5                    5.1 ± 0.4                    0.4430          14         NS
  IADL                  13.0 ± 1.1                   14.4 ± 0.7                   0.7238          14         NS

**Abbreviations:** REAC, radio electric asymmetric brain stimulation; TSV, total score variation; MMSE, Mini-Mental state examination; NPI, Neuropsychiatric inventory; ADL, Activity of Daily Living; IADL, Instrumental Activity of Daily Living; NS, not statistically significant.
